Equities

Predilife SA

ALPRE:PAR

Predilife SA

Actions
Health CareHealth Care Providers
  • Price (EUR)6.06
  • Today's Change0.00 / 0.00%
  • Shares traded90.00
  • 1 Year change-14.65%
  • Beta0.4008
Data delayed at least 15 minutes, as of Jun 24 2022 08:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Predilife SA is a France-based company specialized in the development of predictive tests in the medical industry. The Company operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.

  • Revenue in EUR (TTM)66.39k
  • Net income in EUR-3.14m
  • Incorporated2004
  • Employees18.00
  • Location
    Predilife SAIgr Campus Cancer 1 Batiment Maurice39 Rue Camille DesmoulinsVILLEJUIF 94805FranceFRA
  • Phone+33 142114211
  • Websitehttps://www.predilife.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Theranexus SA0.00-8.15m6.99m17.00--0.8414-----1.62-1.620.002.030.00----0.00-47.44-31.66-51.44-35.11-----------23.980.3426-------69.89---2.28--
IntegraGen SA8.98m-375.02k7.27m43.00--3.30--0.8091-0.0556-0.05561.350.32751.1511.024.53208,827.70-4.82-10.70-10.45-23.8867.6461.77-4.18-11.831.68--0.4815--8.459.97-31.66------
Lysogene SA3.73m-13.61m12.29m23.00------3.29-0.8058-0.80580.2211-0.25400.1549--0.7278162,217.40-56.51-40.97-195.94-126.32-240.74-94.68-364.75-151.78---41.801.79---72.09---167.31--134.89--
Theravet SA-100.00bn-100.00bn12.86m--------------------------------------------------------------
Biophytis SA0.00-31.25m17.50m22.00--2.53-----0.2627-0.26270.000.04220.00----0.00-98.46-86.90-357.70-211.11-----------6.050.7294-------22.45--21.67--
Plant Advanced Technologies PAT SA1.92m-1.04m18.65m32.00--2.48--9.71-0.9501-0.95011.776.890.12320.72949.3960,035.63-6.52-3.64-8.58-4.4049.3165.53-52.96-38.711.09-20.880.4156--7.104.40-22.71------
Predilife SA66.39k-3.14m22.18m18.00------334.11-0.8665-0.86650.0181-0.3220.019--2.325,650.21-89.91---122.82--21.24---4,729.25-----13.231.29--125.49---7.06------
genOway SA12.44m-405.15k29.40m121.00--1.8925.002.36-0.0427-0.04271.661.720.4479-0.03092.46105,461.90-1.461.57-1.982.51100.2890.86-3.262.712.03-3.000.40070.0016.486.3333.69--94.79--
Sensorion SA0.00-15.14m31.18m39.00--0.7076-----0.1899-0.18990.000.55110.00----0.00-23.84-35.94-26.99-47.78-----------133.920.0846-------68.60--14.33--
Adocia SA1.44m-22.75m32.48m112.00------22.49-3.22-3.220.2046-1.910.0384--13.9512,892.86-60.50-23.00-111.70-30.70-----1,575.76-92.050.9079-5.721.67--71.70-42.252.44---46.29--
Data as of Jun 24 2022. Currency figures normalised to Predilife SA's reporting currency: Euro EUR
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.